Objective: to study the efficacy of Panavir rectal suppositories in the treatment of sexually active patients of reproductive age with papillomavirus infection. Subjects and methods. Forty patients with anogenital papillomavirus infection were examined. Group 1 consisted of 20 patients with the clinical manifestations of papillomavirus infection - condyloma acuminata. Group 2 included 20 women without clinical manifestations, whose diagnosis was established on the basis of human papillomavirus DNA detection. The diagnosis was verified by polymerase chain reaction. All the patients were given Panavir rectal suppositories in a daily dose of 200 mg for 10 days. Radio waves were used to destroy anogenital warts in Group 1 patients. The patients were examined using laboratory monitoring immediately and 30, 60, and 90 days after therapy. Results. Following 3 months of Panavir therapy in combination with radio wave mass destruction, human papillomavirus DNA was not detected in 80% of the patients; remission was recorded in 90%. After 3 months of Panavir use, 85% of the patients with latent infection were found to cease human papillomavirus DNA excretion. Conclusion. The high clinical efficacy of Panavir suppositories permits one to recommend the agent in this formulation for wide practical application.